CD38 and plasma cell myeloma: Considering how rapidly the treatment of MM is evolving, soon, with the introduction of quadruplet regimens for newly diagnosed myeloma, most patients will be exposed in their earlier lines of therapy to PIs, IMiDs, and CD38 monoclonal antibodies.